{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:38Z","timestamp":1761870338100,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.04.006","type":"journal-article","created":{"date-parts":[[2011,5,22]],"date-time":"2011-05-22T02:43:37Z","timestamp":1306032217000},"page":"S91-S95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S1","title":["Management Options for Follicular Lymphoma: Observe; R-CHOP; B-R; Others?"],"prefix":"10.1016","volume":"11","author":[{"given":"Peter","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.04.006_bib1","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low grade lymphoma","volume":"92","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib2","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.743","article-title":"Radiation therapy for localized low grade non-Hodgkin's lymphomas","volume":"23","author":"Tsang","year":"2005","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib4","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.04.006_bib5","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib7","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib8","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2011.04.006_bib9","article-title":"Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcomes of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group after a follow up of 58 months","volume":"112","author":"Buske","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib10","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib12","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, on interferon alfa","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib14","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas","volume":"16","author":"Solal-Celigny","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma: the international non-Hodgkin's lymphoma prognostic factors project","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.04.006_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","article-title":"Applicability of the International Index for aggressive lymphomas to patients with low grade lymphoma","volume":"12","author":"Lopez-Guillermo","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib18","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.6.6","article-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asumptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a): a preliminiary analysis","volume":"116","author":"Ardeshna","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkins' lymphoma","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3420.3420","article-title":"Preliminary pharmacokinetic analysis of Eastern Cooperative Oncology Group protocol E4402: rituximab extended schedule or re-treatment trial (RESORT)","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1714.1714","article-title":"A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma","volume":"114","author":"Fowler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/oxfordjournals.annonc.a010720","article-title":"Is there any place for a wait-and-see policy in stage I0 follicular lymphoma?","volume":"7","author":"Soubeyran","year":"1996","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2011.04.006_bib24","article-title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiatin therapy alone","volume":"22","author":"Petersen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low grade follicular lymphoma?","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiation Oncology Biol Phys"},{"key":"10.1016\/j.clml.2011.04.006_bib27","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":"Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma","volume":"22","author":"Zinzani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1706.1706","article-title":"Rituximab maintenance versus observation after short term chemo-immunotherapy R-FND as first line treatment in elderly patients with advanced follicular lymphoma","volume":"114","author":"Vitolo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdp297","article-title":"The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy","volume":"21","author":"Gill","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib31","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1002\/cncr.25280","article-title":"Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-na\u00efve, recurrent\/refractory follicular non-Hodgkin lymphoma with a high tumor burden","volume":"116","author":"Morschhauser","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.04.006_bib32","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.405.405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib34","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib35","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.1998.16.7.2339","article-title":"Quality-of-life-adjusted survival analysis of interferon alfa-2b for advanced follicular lymphoma: an aid to clinical decision making","volume":"16","author":"Cole","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib36","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation with yttrium-90 ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib37","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3056.3056","article-title":"R-FND followed by radioimmunotherapy for high-risk follicular lymphoma","volume":"112","author":"McLaughlin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib39","volume":"110","author":"Gregory","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib40","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2008-01-132142","article-title":"Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab","volume":"112","author":"Gopal","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib41","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","article-title":"Phase 1\/2 study of fractionated 131-I rituximab in low grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy","volume":"113","author":"Illidge","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131-I tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.04.006_bib43","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib44","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advance indolent lymphoma","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib45","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed-resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib46","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib47","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles","year":"2010","journal-title":"J Cin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.04.006_bib49","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2011.04.006_bib50","article-title":"High dose chemotherapy and autologous stem cell transplantation in the primary therapy of advanced follicular lymphoma in adults: a systematic review and meta-analysis of randomized clinical trials","volume":"114","author":"Al-Khabori","year":"2009","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2011.04.006_bib51","volume":"114","author":"Tarella","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.006_bib52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib53","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves prdogressionn-free survival and survival in relapsed follicular non-Hodgkin's lyphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib54","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at the time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.006_bib55","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2006.01.001","article-title":"The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma","volume":"20","author":"van Besien","year":"2006","journal-title":"Blood Reviews"},{"key":"10.1016\/j.clml.2011.04.006_bib56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2011.04.006_bib57","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation-2009.1.610","article-title":"Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy","author":"van Besien","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2011.04.006_bib58","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","volume":"364","author":"Zarin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.04.006_bib59","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:02Z","timestamp":1761870122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":59,"alternative-id":["S2152265011000553"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.04.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Options for Follicular Lymphoma: Observe; R-CHOP; B-R; Others?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}